Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Background Intrahepatic cholangiocarcinoma (ICC) is rising in clinical importance due to the
increasing incidence worldwide, poor prognosis, and suboptimal response to therapies …

Abstract Sorafenib (Nexavar, BAY43‑9006 or Sora) is the first molecular targeted agent that
has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC) …

HepG2 cells were exposed to sorafenib, irinotecan, and oxaliplatin and then subjected to
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …

This study aimed to investigate the effects of Tarantula cubensis alcohol extract (TCAE,
Theranekron) and Sorafenib (S) treatments on carcinogenesis, apoptosis and biochemical …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Background Given the well-documented adverse side effects of sorafenib, many sorafenib-
treated patients may need the reduced initial dose of the compound, and an alternative …